Soumya M S, Sreenivas V, Nadig Malavika S, James Rhea Merin, Pinheiro Thara, Balasubramanyam A M, Nayar Ravi C, Charles R Regan, Kumar Ashwin
Department of Otorhinolaryngology, Head and Neck Surgery, St. John's Medical College Hospital Bangalore, Bangalore, India.
St John's Medical College Hospital, Sarjapur-Marathahalli Rd, Beside Bank Of Baroda, John Nagar, Koramangala, Bengaluru, Karnataka 560034 India.
Indian J Otolaryngol Head Neck Surg. 2024 Oct;76(5):4189-4199. doi: 10.1007/s12070-024-04813-6. Epub 2024 Jun 25.
Obstructive sleep apnea (OSA) is identified by instances of either full or partial collapse of the airway during sleep, leading to reduced oxygen levels or awakening from sleep. This disruption causes interrupted and insufficient sleep, impacting cardiovascular well-being, mental health, and overall quality of life. Pediatric OSA is more challenging to diagnose and a single apnoea is considered to be significant in this age group. A hospital based prospective study with 100 children between the ages of 4 and 12 years with sleep disordered breathing. Evaluated for the severity of obstructive sleep apnea and also assessed if surgery was beneficial to treat OSA in mild cases. General physical examination, evaluation of facial/oral features were conducted to rule out adenoid facies. Additionally, ENT examination was conducted. Medical history and lateral neck radiographs were reviewed, and the paediatric sleep questionnaire was administered to evaluate neurobehavioral morbidities associated with OSA. These children were evaluated for sleep disorders by conducting the polysomnography. Pediatric sleep questionnaire was also administered. The scoring and results analysis were conducted according to standardised guidelines provided by the American association for sleep medicine. Furthermore, medical management protocols were outlined, including a 6-week course of intranasal steroids and leukotriene receptor antagonist therapy, with consideration of adenotonsillectomy for patients failing medical therapy. In our study on paediatric obstructive sleep apnea (OSA), medical treatment significantly reduced clinical symptom scores in cases of mild OSA, as evidenced by pre- and post-parental sleep questionnaire scores of 23.62 ± 8.24 and 13.55 ± 6.05, respectively (paired samples test, = 0.00). Similarly, both the pre- and post-Apnoea/Hypopnoea Index (AHI) scores (2.278 ± 1.5658 and 1.19 ± 1.420) and central sleep apnea index scores (1.252 ± 0.8972 and 0.61 ± 0.815) significantly improved post-treatment (paired samples test, = 0.03, respectively). Additionally, significant changes were observed in tonsillar grade after the 12-week medication course, and sleep architecture showed notable improvement during the repeat follow-up study. These findings highlight the efficacy of treatment interventions in alleviating symptoms and enhancing sleep efficiency in paediatric OSA. The findings of this study underscore the efficacy of a medical management using intranasal corticosteroids and oral montelukast in mitigating the severity of mild obstructive sleep apnea (OSA) in children. This research substantiates the therapeutic value of corticosteroids and oral montelukast in paediatric patients with mild OSA, offering compelling evidence for their use as beneficial interventions in this population.
The online version contains supplementary material available at 10.1007/s12070-024-04813-6.
阻塞性睡眠呼吸暂停(OSA)通过睡眠期间气道完全或部分塌陷的情况来识别,这会导致氧气水平降低或睡眠中觉醒。这种干扰会导致睡眠中断和不足,影响心血管健康、心理健康和整体生活质量。小儿OSA的诊断更具挑战性,在这个年龄组中单次呼吸暂停被认为是有意义的。一项基于医院的前瞻性研究,对100名4至12岁有睡眠呼吸障碍的儿童进行了研究。评估阻塞性睡眠呼吸暂停的严重程度,并评估手术对轻度病例治疗OSA是否有益。进行了一般体格检查、面部/口腔特征评估以排除腺样体面容。此外,还进行了耳鼻喉检查。回顾了病史和颈部侧位X线片,并发放了儿童睡眠问卷以评估与OSA相关的神经行为疾病。通过多导睡眠图对这些儿童进行睡眠障碍评估。还发放了儿童睡眠问卷。根据美国睡眠医学协会提供的标准化指南进行评分和结果分析。此外,概述了医学管理方案,包括为期6周的鼻内类固醇和白三烯受体拮抗剂治疗疗程,对于药物治疗失败的患者考虑进行腺样体扁桃体切除术。在我们关于小儿阻塞性睡眠呼吸暂停(OSA)的研究中,药物治疗显著降低了轻度OSA病例的临床症状评分,父母睡眠问卷前后评分分别为23.62±8.24和13.55±6.05,这证明了这一点(配对样本检验,P = 0.00)。同样,呼吸暂停/低通气指数(AHI)前后评分(2.278±1.5658和1.19±1.420)以及中枢性睡眠呼吸暂停指数评分(1.252±0.8972和0.61±0.815)在治疗后均显著改善(配对样本检验,P分别为0.03)。此外,在为期12周的药物疗程后扁桃体分级有显著变化,并且在重复随访研究期间睡眠结构有显著改善。这些发现突出了治疗干预在减轻小儿OSA症状和提高睡眠效率方面的疗效。本研究结果强调了使用鼻内皮质类固醇和口服孟鲁司特进行医学管理在减轻儿童轻度阻塞性睡眠呼吸暂停(OSA)严重程度方面的疗效。这项研究证实了皮质类固醇和口服孟鲁司特在小儿轻度OSA患者中的治疗价值,为它们作为该人群的有益干预措施提供了有力证据。
在线版本包含可在10.1007/s12070-024-04813-6获取的补充材料。